Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 3
2001 7
2002 6
2003 8
2004 4
2005 12
2006 10
2007 11
2008 9
2009 8
2010 9
2011 9
2012 2
2013 2
2014 3
2015 1
2016 2
2017 1
2019 2
2020 4
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 19537304

108 results
Results by year
Filters applied: . Clear all
Page 1
Impact of induction therapy on bacterial infections and long-term outcome in adult intestinal and multivisceral transplantation: a comparison of two different induction protocols: daclizumab vs. alemtuzumab.
Kimura T, Lauro A, Cescon M, Zanfi C, Dazzi A, Ercolani G, Grazi GL, Vivarelli M, Ravaioli M, Del Gaudio M, Cucchetti A, Zanello M, LaBarba G, Pironi L, Lazzarotto T, Pinna AD. Kimura T, et al. Clin Transplant. 2009 Jun-Jul;23(3):420-5. doi: 10.1111/j.1399-0012.2008.00922.x. Clin Transplant. 2009. PMID: 19537304
Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD. Zanfi C, et al. Transplant Proc. 2010 Jan-Feb;42(1):35-8. doi: 10.1016/j.transproceed.2009.12.019. Transplant Proc. 2010. PMID: 20172276
Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.
Elimelakh M, Dayton V, Park KS, Gruessner AC, Sutherland D, Howe RB, Reding MT, Eastlund T, van Burik JA, Singleton TP, Gruessner RW, Key NS. Elimelakh M, et al. Haematologica. 2007 Aug;92(8):1029-36. doi: 10.3324/haematol.10733. Epub 2007 Jul 20. Haematologica. 2007. PMID: 17640860 Free article.
Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial.
Chan K, Taube D, Roufosse C, Cook T, Brookes P, Goodall D, Galliford J, Cairns T, Dorling A, Duncan N, Hakim N, Palmer A, Papalois V, Warrens AN, Willicombe M, McLean AG. Chan K, et al. Transplantation. 2011 Oct 15;92(7):774-80. doi: 10.1097/TP.0b013e31822ca7ca. Transplantation. 2011. PMID: 21836540 Clinical Trial.
Kidney after nonrenal transplantation-the impact of alemtuzumab induction.
Shapiro R, Basu A, Tan HP, Morgan C, Sharma V, Blisard D, Randhawa PS, Dvorchik I, McCauley J, Ellis D, Marsh JW, Webber S, Kurland G, McCurry KR, Abu-Elmagd K, Mazariegos G, Starzl TE. Shapiro R, et al. Transplantation. 2009 Sep 27;88(6):799-802. doi: 10.1097/TP.0b013e3181b4aaf5. Transplantation. 2009. PMID: 19920779 Free PMC article.
Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
Lauro A, Amaduzzi A, Dazzi A, Ercolani G, Zanfi C, Golfieri L, Grazi GL, Vivarelli M, Cescon M, Varotti G, Del Gaudio M, Ravaioli M, Siniscalchi A, Faenza S, D'Errico A, Di Simone M, Pironi L, Pinna AD. Lauro A, et al. Dig Liver Dis. 2007 Mar;39(3):253-6. doi: 10.1016/j.dld.2006.11.012. Epub 2007 Feb 1. Dig Liver Dis. 2007. PMID: 17275428
A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
Ciancio G, Burke GW, Gaynor JJ, Carreno MR, Cirocco RE, Mathew JM, Mattiazzi A, Cordovilla T, Roth D, Kupin W, Rosen A, Esquenazi V, Tzakis AG, Miller J. Ciancio G, et al. Transplantation. 2005 Aug 27;80(4):457-65. doi: 10.1097/01.tp.0000165847.05787.08. Transplantation. 2005. PMID: 16123718 Clinical Trial.
Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS. Woodroffe R, et al. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. doi: 10.3310/hta9210. Health Technol Assess. 2005. PMID: 15899149 Free article. Review.
Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
Abou-Jaoude MM, Ghantous I, Almawi WY. Abou-Jaoude MM, et al. Mol Immunol. 2003 Jul;39(17-18):1083-8. doi: 10.1016/s0161-5890(03)00072-5. Mol Immunol. 2003. PMID: 12835081 Clinical Trial.
A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up.
Ciancio G, Burke GW, Gaynor JJ, Roth D, Kupin W, Rosen A, Cordovilla T, Tueros L, Herrada E, Miller J. Ciancio G, et al. Clin Transplant. 2008 Mar-Apr;22(2):200-10. doi: 10.1111/j.1399-0012.2007.00774.x. Clin Transplant. 2008. PMID: 18339140 Clinical Trial.
108 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback